These findings indicate that intravenously administered CD38‐EVs exhibit greater accessibility to tumour cells compared to EVs, and significantly reduce distribution in the lungs; however, the CD38‐EVs fail to efficiently accumulate at the tumour site. Here, CD38 is linked to neoplasm.